Cellumed, a subsidiary of InskoBi and a specialized manufacturer of bio-medical devices, announced on May 29 that its monthly production record for bone graft products has reached an all-time high. This achievement is the result of company-wide strategies aimed at improving productivity, including process enhancements and expansion of the global raw material supply chain, which have now produced tangible results.
Since receiving approval for a human tissue bank in 2005 and obtaining a license for manufacturing human tissue-based medical devices in 2007, Cellumed has been producing skin and bone graft products. Recently, with the increase in bone and degenerative diseases due to population aging, the bone graft market has been expanding, and related product sales have shown steady growth.
Cellumed’s main products are 'Rafugen DBM (Demineralized Bone Matrix)' for orthopedic use and 'Rafugen Dental' for dental bone grafting. Because these products are used directly in the human body, the company has continuously introduced automated equipment to minimize human error during production. Through its 'Production Process TFT,' Cellumed has focused on ▲ increasing capacity, ▲ standardizing production, and ▲ enhancing safety and convenience in medical settings.
Recently, to stably respond to increased production volumes, Cellumed has expanded its global network and strengthened the stability of its raw material supply. As a result of these enhanced capabilities, the company achieved its highest-ever monthly production volume in May.
Based on this record monthly production, Cellumed expects a significant increase in sales in the second half of the year. With rising demand in the medical device market, the company anticipates not only expanding supply through major hospital and dental networks, but also increasing overseas sales.
A Cellumed representative stated, "This achievement is the result of organizational restructuring centered on the production division and strengthening collaboration among related departments, which has simultaneously improved productivity and stabilized quality. This will enhance our competitiveness in both domestic and international bone graft markets," adding, "We will continue to strengthen our production capabilities and upgrade our supply systems to further expand our presence in the global market."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
